Dr. Johnson

Continuing Dr. West's theme discussing new therapies for patients with acquired resistance, I'd like to answer a few questions about HSP 90 inhibitors that have caught my attention on GRACE over the past few weeks, and in particular, highlight my "pet" targeted agent, AUY922. HSP 90 inhibitors are drugs that many of you already know about-they are being studied in patients with ALK(+)lung cancer and as a 2nd line therapy option for all patients with lung cancer with Taxotere.

Comments

Post Date: 2018-01-11
Original Post: Nodule concern

test test test

Post Date: 2017-09-06
Original Post: Test - forum post

test

Post Date: 2017-08-31
Original Post: SCLC Example Post

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nullam id sapien quis lorem sollicitudin